[A cost-effectiveness analysis of treatment with antiendotoxin monoclonal antibodies in gram-negative sepsis].
Tebas
P
P
D000911:Antibodies, Monoclonal / Q000191:economics* / Q000627:therapeutic use; D061067:Antibodies, Monoclonal, Humanized; D003362:Cost-Benefit Analysis; D004731:Endotoxins / Q000276:immunology*; D006090:Gram-Negative Bacteria; D016905:Gram-Negative Bacterial Infections / Q000191:economics* / Q000628:therapy; D006801:Humans; D013030:Spain
D000911:Antibodies, Monoclonal; D061067:Antibodies, Monoclonal, Humanized; D004731:Endotoxins; C068069:nebacumab
Análisis coste-eficacia del tratamiento con anticuerpos monoclonales antiendotoxina en la sepsis por gramnegativos.